Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 USD | +3.89% | -5.79% | +133.47% |
May. 13 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
May. 08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+133.47% | 600M | |
+52.74% | 55.07B | |
-1.18% | 41.79B | |
+44.64% | 40.22B | |
-7.59% | 28.17B | |
+12.71% | 26.28B | |
-21.20% | 18.93B | |
+7.52% | 13.03B | |
+30.48% | 12.26B | |
+26.13% | 12.21B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating